表紙:調剤薬局の世界市場 (2022年~2030年):市場規模 ( 治療分野・製品・用途・調剤タイプ・無菌性・流通チャネル別)・地域的展望・価格動向・競合市場シェア・予測
市場調査レポート
商品コード
1123575

調剤薬局の世界市場 (2022年~2030年):市場規模 ( 治療分野・製品・用途・調剤タイプ・無菌性・流通チャネル別)・地域的展望・価格動向・競合市場シェア・予測

Compounding Pharmacies Market Size, By Therapeutic Area, Product, Application, Compounding Type, Sterility, Distribution Channel, Regional Outlook, Price Trends, Competitive Market Share & Forecast, 2022-2030

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 530 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
調剤薬局の世界市場 (2022年~2030年):市場規模 ( 治療分野・製品・用途・調剤タイプ・無菌性・流通チャネル別)・地域的展望・価格動向・競合市場シェア・予測
出版日: 2022年08月24日
発行: Global Market Insights Inc.
ページ情報: 英文 530 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

調剤薬局の市場は、先進国でのオーダーメイド医療の普及により、2030年にかけて大きく成長すると予想されています。

また、老年人口の増加と医薬品不足も予測期間を通じて市場成長をさらに促進するものと思われます。

治療分野別で見ると、皮膚科の部門が予測期間中に約6.4%のCAGRを示すと予測されています。皮膚の老化や日焼けなど、皮膚に関する懸念の高まりと、健康な皮膚へのニーズの高まりが、皮膚科用調剤薬の需要を促進する主な要因となっています。

当レポートでは、世界の調剤薬局の市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制環境、償還情勢、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 調剤薬局産業の考察

  • 産業の分類
  • 産業情勢
  • 産業エコシステム分析
  • 産業への影響要因
    • 促進要因
    • 潜在的リスク&課題
  • 成長性分析
  • 規制状況
  • 償還情勢
  • COVID-19影響分析
  • ポーターの分析
  • 競合情勢,
  • PESTEL分析

第4章 調剤薬局市場:治療分野別

  • 主要動向
  • ホルモン補充
  • 疼痛管理
  • 皮膚科
  • 特殊医薬品
  • 栄養補助食品
  • その他

第5章 調剤薬局市場:製品別

  • 主要動向
  • 経口剤
    • 固形製剤
    • 液体製剤
  • 局所剤
    • 軟膏
    • クリーム
    • ゲル
    • ペースト
    • その他
  • 坐剤
    • 座薬
    • 浣腸
    • その他
  • 非経口剤
    • LVP
    • SVP
  • 経鼻剤
  • 点眼剤
  • 点耳薬

第6章 調剤薬局市場:用途別

  • 主要動向
  • 小児
  • 成人
  • 高齢者
  • 動物

第7章 調剤薬局市場:調剤タイプ別

  • 主要動向
  • PIA
  • CUPM
  • PDA
  • その他

第8章 調剤薬局市場:無菌性別

  • 主要動向
  • 無菌
  • 非無菌

第9章 調剤薬局市場:流通チャネル別

  • 主要動向
  • 病院薬局
  • 調剤薬局
  • その他

第10章 調剤薬局市場:地域別

  • 主要動向
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 企業プロファイル

  • 戦略ダッシュボード
  • Athenex Pharma Solutions(Athenex Inc.)
  • B. Braun SE
  • Clinigen Limited
  • Dougherty's Pharmacy, Inc.
  • Fagron
  • Fresenius Kabi
  • Institutional Pharmacy Solutions
  • Lorraine's Pharmacy
  • McGuff Company Inc.(McGuff Compounding Pharmacy Services)
  • Nephron Pharmaceuticals Corporation
  • Pencol Compounding Pharmacy
  • Rx3 Compounding Pharmacy
  • Triangle Compounding Pharmacies
  • Wedgewood Village Pharmacy, Inc.
目次
Product Code: 749

The compounding pharmacies market is speculated to grow massively by 2030 owing to widespread adoption of customized medicine in developed regions. In addition, expanding geriatric population, along with a shortage of drugs, is likely to further propel market growth through the forecast period.

The emergence of the COVID-19 pandemic provided the industry with new opportunities to prosper in recent years. Increasing demand for medications from hospital and compounding pharmacies to curb the spread of the coronavirus infection escalated the utilization of compounded drugs. Furthermore, government authorization to maintain the availability of these drugs aided market expansion.

Moreover, key players in the market have been engaging in rigorous R&D and strategic acquisitions and collaborations to expand their customer base and improve their industry standing. For instance, in March 2022, B. Braun, a German medical and pharmaceutical company, acquired Intermedt Medizin & Technik GmbH, an expert in the preparation of dialysis concentrates. The acquisition was intended to aid the company in expanding its business in the field of dialysis concentrates.

The compounding pharmacies market has been bifurcated in terms of product, therapeutic area, application, sterility, compounding type, distribution channel, and region.

With respect to therapeutic area, the industry has been divided into nutritional supplements, hormone replacement, dermatology, pain management, specialty drugs, and others. The dermatology segment is expected to grow at approximately 6.4% CAGR over the analysis timeframe. Growing skin-related concerns viz., skin aging and sunburns, coupled with soaring need for healthy skin, are major factors that are poised to drive the demand for compounding medicines for dermatological usage. Additionally, the ability of compounded dermatological drugs to accommodate individual needs and overcome issues related to allergies and sensitivities caused by commercially available skin care medications is set to boost segmental progress.

The compounding pharmacies market has been classified based on product into oral, topical, parenteral, rectal, nasal, otic, and ophthalmic. The topical segment size was registered at over $1,727.2 million in 2021 and is slated to attain substantial gains by 2030. The growth is attributed to ease of drug delivery, drug formulations, and rising demand for ointments, gels, creams, patches, lotions, and sprays, especially for pain management owing to their faster action at the site of application. Moreover, prominent R&D activities for the development of innovative topical medications using compounding pharmacies to cater to specific patient requirements are also projected to propel segmental expansion.

From application point of reference, the compounding pharmacies market has been segregated into pediatric, geriatric, adult, and veterinary. In 2021, the pediatric segment accounted for above $1,653.2 million valuation and is estimated to record significant expansion in the coming years. Several benefits of compounded medications, such as dose alteration, ingredient alteration, and the advantage of altering the route of administration, are likely to increase the demand for compounded medications for pediatric usage.

In the regional context, the Middle East & Africa compounding pharmacies industry was valued at nearly $179.4 million in 2021. Burgeoning healthcare expenditure, favorable government initiatives in the healthcare segment, and cost-effectiveness of compounded medications are primed to accelerate the growth of the MEA compounding pharmacies market in the future.

Table of Contents

Chapter 1 Methodology

  • 1.1 Methodology
  • 1.2 Market definitions
  • 1.3 Forecast parameters
  • 1.4 Data sources
    • 1.4.1 Secondary
      • 1.4.1.1 Paid sources
      • 1.4.1.2 Public sources
    • 1.4.2 Primary

Chapter 2 Executive Summary

  • 2.1 Compounding pharmacies industry 360 degree synopsis, 2017 - 2030
    • 2.1.1 Business trends
    • 2.1.2 Therapeutic area trends
    • 2.1.3 Product trends
    • 2.1.4 Application trends
    • 2.1.5 Compounding type trends
    • 2.1.6 Sterility trends
    • 2.1.7 Distribution channel trends
    • 2.1.8 Regional trends

Chapter 3 Compounding Pharmacies Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030
  • 3.3 Industry ecosystem analysis
    • 3.3.1 Distribution channel analysis
  • 3.4 Industry impact forces
    • 3.4.1 Growth drivers
      • 3.4.1.1 Rising geriatric population and improved life expectancy across the globe
      • 3.4.1.2 Rising adoption of customized medicine in the developed regions
      • 3.4.1.3 Shortage of drugs across the globe
      • 3.4.1.4 Benefits of compounded medication
      • 3.4.1.5 Growing drug failure rate
    • 3.4.2 Industry pitfalls & challenges
      • 3.4.2.1 Lack of skilled lab technicians and pharmacists in developed economies
      • 3.4.2.2 High cost of equipment and maintenance of sterile environment
      • 3.4.2.3 Volatile regulatory scenario
      • 3.4.2.4 Consumer perception towards compounded drugs
  • 3.5 Growth potential analysis
    • 3.5.1 By therapeutic area
    • 3.5.2 By product
    • 3.5.3 By application
    • 3.5.4 By compounding type
    • 3.5.5 By sterility
    • 3.5.6 By distribution type
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
    • 3.6.3 Australia
  • 3.7 Reimbursement landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Australia
  • 3.8 COVID- 19 impact analysis
  • 3.9 Porter's analysis
  • 3.10 Competitive landscape, 2021
    • 3.10.1 Company matrix analysis, 2021
  • 3.11 PESTEL analysis

Chapter 4 Compounding Pharmacies Market, By Therapeutic Area

  • 4.1 Key segment trends
  • 4.2 Hormone replacement
    • 4.2.1 Market size, by region, 2017-2030 (USD Million)
  • 4.3 Pain management
    • 4.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.4 Dermatology applications
    • 4.4.1 Market size, by region, 2017-2030 (USD Million)
  • 4.5 Specialty drugs
    • 4.5.1 Market size, by region, 2017-2030 (USD Million)
  • 4.6 Nutritional supplements
    • 4.6.1 Market size, by region, 2017-2030 (USD Million)
  • 4.7 Others
    • 4.7.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Compounding Pharmacies Market, By Product

  • 5.1 Key segment trends
  • 5.2 Oral
    • 5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.2 Solid preparations
      • 5.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.2 Tablets
        • 5.2.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.3 Capsules
        • 5.2.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.4 Granules
        • 5.2.2.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.5 Powder
        • 5.2.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.6 Others
        • 5.2.2.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.3 Liquid preparations
      • 5.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.2 Solution
        • 5.2.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.3 Suspension
        • 5.2.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.4 Emulsion
        • 5.2.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.5 Syrup
        • 5.2.3.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.6 Others
        • 5.2.3.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.3 Topical
    • 5.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.2 Ointments
      • 5.3.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.3 Creams
      • 5.3.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.4 Gels
      • 5.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.5 Pastes
      • 5.3.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.6 Others
      • 5.3.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.4 Rectal
    • 5.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.2 Suppositories
      • 5.4.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.3 Enema
      • 5.4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.4 Others
      • 5.4.4.1 Market size, by region, 2017-2030 (USD Million)
  • 5.5 Parenteral
    • 5.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.5.2 LVP
      • 5.5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.5.3 SVP
      • 5.5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 5.6 Nasal
    • 5.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.7 Ophthalmic
    • 5.7.1 Market size, by region, 2017-2030 (USD Million)
  • 5.8 Otic
    • 5.8.1 Market size, by region, 2017-2030 (USD Million)

Chapter 6 Compounding Pharmacies Market, By Application

  • 6.1 Key segment trends
  • 6.2 Pediatric
    • 6.2.1 Market size, by region, 2017-2030 (USD Million)
  • 6.3 Adult
    • 6.3.1 Market size, by region, 2017-2030 (USD Million)
  • 6.4 Geriatric
    • 6.4.1 Market size, by region, 2017-2030 (USD Million)
  • 6.5 Veterinary
    • 6.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 7 Compounding Pharmacies Market, By Compounding Type

  • 7.1 Key segment trends
  • 7.2 Pharmaceutical Ingredient Alteration (PIA)
    • 7.2.1 Market size, by region, 2017-2030 (USD Million)
  • 7.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 7.3.1 Market size, by region, 2017-2030 (USD Million)
  • 7.4 Pharmaceutical Dosage Alteration (PDA)
    • 7.4.1 Market size, by region, 2017-2030 (USD Million)
  • 7.5 Others
    • 7.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 8 Compounding Pharmacies Market, By Sterility

  • 8.1 Key segment trends
  • 8.2 Sterile
    • 8.2.1 Market size, by region, 2017-2030 (USD Million)
  • 8.3 Non-sterile
    • 8.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 9 Compounding Pharmacies Market, By Distribution Channel

  • 9.1 Key segment trends
  • 9.2 Hospital pharmacy
    • 9.2.1 Market size, by region, 2017-2030 (USD Million)
  • 9.3 Compounding pharmacy
    • 9.3.1 Market size, by region, 2017-2030 (USD Million)
  • 9.4 Others
    • 9.4.1 Market size, by region, 2017-2030 (USD Million)

Chapter 10 Compounding Pharmacies Market, By Region

  • 10.1 Key regional trends
  • 10.2 North America
    • 10.2.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.2.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.2.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.2.3.1 Market size, by oral, 2017 - 2030
        • 10.2.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.2.3.2 Market size, by topical, 2017 - 2030
      • 10.2.3.3 Market size, by rectal, 2017 - 2030
      • 10.2.3.4 Market size, by parenteral, 2017 - 2030
    • 10.2.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.2.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.2.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.2.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.2.8 U.S.
      • 10.2.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.2.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.2.8.2.1 Market size, by oral, 2017 - 2030
        • 10.2.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.2.8.2.2 Market size, by topical, 2017 - 2030
        • 10.2.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.2.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.2.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.2.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.2.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.2.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.2.9 Canada
      • 10.2.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.2.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.2.9.2.1 Market size, by oral, 2017 - 2030
        • 10.2.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.2.9.2.2 Market size, by topical, 2017 - 2030
        • 10.2.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.2.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.2.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.2.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.2.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.2.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.3 Europe
    • 10.3.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.3.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.3.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.3.3.1 Market size, by oral, 2017 - 2030
        • 10.3.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.3.3.2 Market size, by topical, 2017 - 2030
      • 10.3.3.3 Market size, by rectal, 2017 - 2030
      • 10.3.3.4 Market size, by parenteral, 2017 - 2030
    • 10.3.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.3.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.3.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.3.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.8 Germany
      • 10.3.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.8.2.1 Market size, by oral, 2017 - 2030
        • 10.3.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.8.2.2 Market size, by topical, 2017 - 2030
        • 10.3.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.9 UK
      • 10.3.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.9.2.1 Market size, by oral, 2017 - 2030
        • 10.3.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.9.2.2 Market size, by topical, 2017 - 2030
        • 10.3.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.10 France
      • 10.3.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.10.2.1 Market size, by oral, 2017 - 2030
        • 10.3.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.10.2.2 Market size, by topical, 2017 - 2030
        • 10.3.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.11 Italy
      • 10.3.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.11.2.1 Market size, by oral, 2017 - 2030
        • 10.3.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.11.2.2 Market size, by topical, 2017 - 2030
        • 10.3.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.12 Spain
      • 10.3.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.12.2.1 Market size, by oral, 2017 - 2030
        • 10.3.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.12.2.2 Market size, by topical, 2017 - 2030
        • 10.3.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.13 Poland
      • 10.3.13.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.13.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.13.2.1 Market size, by oral, 2017 - 2030
        • 10.3.13.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.13.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.13.2.2 Market size, by topical, 2017 - 2030
        • 10.3.13.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.13.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.13.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.13.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.13.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.13.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.14 Ukraine
      • 10.3.14.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.14.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.14.2.1 Market size, by oral, 2017 - 2030
        • 10.3.14.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.14.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.14.2.2 Market size, by topical, 2017 - 2030
        • 10.3.14.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.14.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.14.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.14.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.14.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.14.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.15 Greece
      • 10.3.15.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.15.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.15.2.1 Market size, by oral, 2017 - 2030
        • 10.3.15.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.15.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.15.2.2 Market size, by topical, 2017 - 2030
        • 10.3.15.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.15.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.15.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.15.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.15.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.15.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.16 Sweden
      • 10.3.16.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.16.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.16.2.1 Market size, by oral, 2017 - 2030
        • 10.3.16.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.16.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.16.2.2 Market size, by topical, 2017 - 2030
        • 10.3.16.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.16.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.16.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.16.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.16.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.16.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.17 Norway
      • 10.3.17.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.17.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.17.2.1 Market size, by oral, 2017 - 2030
        • 10.3.17.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.17.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.17.2.2 Market size, by topical, 2017 - 2030
        • 10.3.17.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.17.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.17.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.17.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.17.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.17.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.18 Belgium
      • 10.3.18.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.18.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.18.2.1 Market size, by oral, 2017 - 2030
        • 10.3.18.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.18.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.18.2.2 Market size, by topical, 2017 - 2030
        • 10.3.18.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.18.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.18.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.18.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.18.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.18.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.19 Czech Republic
      • 10.3.19.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.19.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.19.2.1 Market size, by oral, 2017 - 2030
        • 10.3.19.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.19.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.19.2.2 Market size, by topical, 2017 - 2030
        • 10.3.19.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.19.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.19.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.19.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.19.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.19.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.20 Finland
      • 10.3.20.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.20.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.20.2.1 Market size, by oral, 2017 - 2030
        • 10.3.20.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.20.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.20.2.2 Market size, by topical, 2017 - 2030
        • 10.3.20.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.20.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.20.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.20.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.20.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.20.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.21 Russia
      • 10.3.21.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.21.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.21.2.1 Market size, by oral, 2017 - 2030
        • 10.3.21.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.21.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.21.2.2 Market size, by topical, 2017 - 2030
        • 10.3.21.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.21.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.21.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.21.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.21.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.21.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.4 Asia Pacific
    • 10.4.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.4.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.4.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.4.3.1 Market size, by oral, 2017 - 2030
        • 10.4.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.4.3.2 Market size, by topical, 2017 - 2030
      • 10.4.3.3 Market size, by rectal, 2017 - 2030
      • 10.4.3.4 Market size, by parenteral, 2017 - 2030
    • 10.4.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.4.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.4.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.4.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.8 Japan
      • 10.4.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.8.2.1 Market size, by oral, 2017 - 2030
        • 10.4.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.8.2.2 Market size, by topical, 2017 - 2030
        • 10.4.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.9 China
      • 10.4.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.9.2.1 Market size, by oral, 2017 - 2030
        • 10.4.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.9.2.2 Market size, by topical, 2017 - 2030
        • 10.4.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.10 India
      • 10.4.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.10.2.1 Market size, by oral, 2017 - 2030
        • 10.4.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.10.2.2 Market size, by topical, 2017 - 2030
        • 10.4.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.11 Singapore
      • 10.4.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.11.2.1 Market size, by oral, 2017 - 2030
        • 10.4.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.11.2.2 Market size, by topical, 2017 - 2030
        • 10.4.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.12 Australia
      • 10.4.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.12.2.1 Market size, by oral, 2017 - 2030
        • 10.4.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.12.2.2 Market size, by topical, 2017 - 2030
        • 10.4.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.5 Latin America
    • 10.5.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.5.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.5.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.5.3.1 Market size, by oral, 2017 - 2030
        • 10.5.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.5.3.2 Market size, by topical, 2017 - 2030
      • 10.5.3.3 Market size, by rectal, 2017 - 2030
      • 10.5.3.4 Market size, by parenteral, 2017 - 2030
    • 10.5.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.5.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.5.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.5.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.8 Brazil
      • 10.5.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.8.2.1 Market size, by oral, 2017 - 2030
        • 10.5.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.8.2.2 Market size, by topical, 2017 - 2030
        • 10.5.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.9 Mexico
      • 10.5.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.9.2.1 Market size, by oral, 2017 - 2030
        • 10.5.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.9.2.2 Market size, by topical, 2017 - 2030
        • 10.5.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.10 Argentina
      • 10.5.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.10.2.1 Market size, by oral, 2017 - 2030
        • 10.5.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.10.2.2 Market size, by topical, 2017 - 2030
        • 10.5.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.6 Middle East & Africa
    • 10.6.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.6.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.6.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.6.3.1 Market size, by oral, 2017 - 2030
        • 10.6.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.6.3.2 Market size, by topical, 2017 - 2030
      • 10.6.3.3 Market size, by rectal, 2017 - 2030
      • 10.6.3.4 Market size, by parenteral, 2017 - 2030
    • 10.6.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.6.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.6.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.6.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.8 Saudi Arabia
      • 10.6.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.8.2.1 Market size, by oral, 2017 - 2030
        • 10.6.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.8.2.2 Market size, by topical, 2017 - 2030
        • 10.6.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.9 UAE
      • 10.6.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.9.2.1 Market size, by oral, 2017 - 2030
        • 10.6.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.9.2.2 Market size, by topical, 2017 - 2030
        • 10.6.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.10 South Africa
      • 10.6.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.10.2.1 Market size, by oral, 2017 - 2030
        • 10.6.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.10.2.2 Market size, by topical, 2017 - 2030
        • 10.6.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.11 Qatar
      • 10.6.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.11.2.1 Market size, by oral, 2017 - 2030
        • 10.6.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.11.2.2 Market size, by topical, 2017 - 2030
        • 10.6.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.12 Kuwait
      • 10.6.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.12.2.1 Market size, by oral, 2017 - 2030
        • 10.6.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.12.2.2 Market size, by topical, 2017 - 2030
        • 10.6.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)

Chapter 11 Company Profiles

  • 11.1 Strategy dashboard, 2021
  • 11.2 Athenex Pharma Solutions (Athenex Inc.)
    • 11.2.1 Business overview
    • 11.2.2 Financial data
    • 11.2.3 Product landscape
    • 11.2.4 Strategic outlook
    • 11.2.5 SWOT analysis
  • 11.3 B. Braun SE
    • 11.3.1 Business overview
    • 11.3.2 Financial data
    • 11.3.3 Product landscape
    • 11.3.4 Strategic outlook
    • 11.3.5 SWOT analysis
  • 11.4 Clinigen Limited
    • 11.4.1 Business overview
    • 11.4.2 Financial data
    • 11.4.3 Product landscape
    • 11.4.4 Strategic outlook
    • 11.4.5 SWOT analysis
  • 11.5 Dougherty's Pharmacy, Inc.
    • 11.5.1 Business overview
    • 11.5.2 Financial data
    • 11.5.3 Product landscape
    • 11.5.4 Strategic outlook
    • 11.5.5 SWOT analysis
  • 11.6 Fagron
    • 11.6.1 Business overview
    • 11.6.2 Financial data
    • 11.6.3 Product landscape
    • 11.6.4 Strategic outlook
    • 11.6.5 SWOT analysis
  • 11.7 Fresenius Kabi
    • 11.7.1 Business overview
    • 11.7.2 Financial data
    • 11.7.3 Product landscape
    • 11.7.4 Strategic outlook
    • 11.7.5 SWOT analysis
  • 11.8 Institutional Pharmacy Solutions
    • 11.8.1 Business overview
    • 11.8.2 Financial data
    • 11.8.3 Product landscape
    • 11.8.4 Strategic outlook
    • 11.8.5 SWOT analysis
  • 11.9 Lorraine's Pharmacy
    • 11.9.1 Business overview
    • 11.9.2 Financial data
    • 11.9.3 Product landscape
    • 11.9.4 Strategic outlook
    • 11.9.5 SWOT analysis
  • 11.10 McGuff Company Inc. (McGuff Compounding Pharmacy Services)
    • 11.10.1 Business overview
    • 11.10.2 Financial data
    • 11.10.3 Product landscape
    • 11.10.4 Strategic outlook
    • 11.10.5 SWOT analysis
  • 11.11 Nephron Pharmaceuticals Corporation
    • 11.11.1 Business overview
    • 11.11.2 Financial data
    • 11.11.3 Product landscape
    • 11.11.4 Strategic outlook
    • 11.11.5 SWOT analysis
  • 11.12 Pencol Compounding Pharmacy
    • 11.12.1 Business overview
    • 11.12.2 Financial data
    • 11.12.3 Product landscape
    • 11.12.4 Strategic outlook
    • 11.12.5 SWOT analysis
  • 11.13 Rx3 Compounding Pharmacy
    • 11.13.1 Business overview
    • 11.13.2 Financial data
    • 11.13.3 Product landscape
    • 11.13.4 Strategic outlook
    • 11.13.5 SWOT analysis
  • 11.14 Triangle Compounding Pharmacies
    • 11.14.1 Business overview
    • 11.14.2 Financial data
    • 11.14.3 Product landscape
    • 11.14.4 Strategic outlook
    • 11.14.5 SWOT analysis
  • 11.15 Wedgewood Village Pharmacy, Inc.
    • 11.15.1 Business overview
    • 11.15.2 Financial data
    • 11.15.3 Product landscape
    • 11.15.4 Strategic outlook
    • 11.15.5 SWOT analysis